AU2003232848A8 - Phenylaminopyrimidines and their use as rho-kinase inhibitors - Google Patents

Phenylaminopyrimidines and their use as rho-kinase inhibitors

Info

Publication number
AU2003232848A8
AU2003232848A8 AU2003232848A AU2003232848A AU2003232848A8 AU 2003232848 A8 AU2003232848 A8 AU 2003232848A8 AU 2003232848 A AU2003232848 A AU 2003232848A AU 2003232848 A AU2003232848 A AU 2003232848A AU 2003232848 A8 AU2003232848 A8 AU 2003232848A8
Authority
AU
Australia
Prior art keywords
phenylaminopyrimidines
rho
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003232848A
Other versions
AU2003232848A1 (en
Inventor
Heike Heckroth
Raimund Kast
Heimo Ehmke
Thomas Schenke
Johannes-Peter Stasch
Samir Bennabi
Elke Stahl
Marcus Bauser
Achim Feurer
Klaus Munter
Jens Erguden
Dieter Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2003232848A1 publication Critical patent/AU2003232848A1/en
Publication of AU2003232848A8 publication Critical patent/AU2003232848A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
AU2003232848A 2002-06-17 2003-06-04 Phenylaminopyrimidines and their use as rho-kinase inhibitors Abandoned AU2003232848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10226943.2 2002-06-17
DE10226943A DE10226943A1 (en) 2002-06-17 2002-06-17 Phenylaminopyrimidines and their use
PCT/EP2003/005827 WO2003106450A1 (en) 2002-06-17 2003-06-04 Phenylaminopyrimidines and their use as rho-kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2003232848A1 AU2003232848A1 (en) 2003-12-31
AU2003232848A8 true AU2003232848A8 (en) 2003-12-31

Family

ID=29719161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232848A Abandoned AU2003232848A1 (en) 2002-06-17 2003-06-04 Phenylaminopyrimidines and their use as rho-kinase inhibitors

Country Status (7)

Country Link
EP (1) EP1515965B1 (en)
JP (1) JP4559851B2 (en)
AU (1) AU2003232848A1 (en)
CA (1) CA2489452C (en)
DE (2) DE10226943A1 (en)
ES (1) ES2353279T3 (en)
WO (1) WO2003106450A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50304983D1 (en) * 2002-10-28 2006-10-19 Bayer Healthcare Ag HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASEINHIBITORS
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
US20040223942A1 (en) * 2003-03-06 2004-11-11 Kao Corporation Skin aging-preventing or improving agent
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
US20070275990A1 (en) * 2003-11-13 2007-11-29 Ono Pharmaceutical Co., Ltd. Heterocyclic Spiro Compound
DE102004017438A1 (en) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituted phenylaminopyrimidines
DE102004020570A1 (en) * 2004-04-27 2005-11-24 Bayer Healthcare Ag Substituted phenylaminopyrimidines
WO2006034446A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
EP1869482A1 (en) * 2005-04-08 2007-12-26 Bayer Pharmaceuticals Corporation Pyrimidine derivatives
EP1869014A2 (en) * 2005-04-08 2007-12-26 Bayer Pharmaceuticals Corporation Pyrimidine derivatives
NL2000323C2 (en) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
TWI552752B (en) * 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 Heteroaryl compounds and uses thereof
IT1396182B1 (en) * 2009-07-29 2012-11-16 Italiana Sint Spa CHEMICAL SYNTHESIS OF (4AS, 7AS) -OTTAIDRO-1H-PIRROLO [3,4-B] PYRIDINE, INTERMEDIATE OF MOXIFLOXACINE
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
CN103221410B (en) 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and the treatment to relative obstacle
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Crystalline free-plate habit of l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid
SI3426251T1 (en) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
JP2020507611A (en) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Compounds and methods for the treatment of primary biliary cholangitis
CN110903285A (en) * 2019-12-13 2020-03-24 南京恒道医药科技有限公司 Method for producing moxifloxacin side chain by using secondary rectification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432493A (en) * 1966-06-27 1969-03-11 Abbott Lab Substituted sulfanilamides
US3478030A (en) * 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
JP4212149B2 (en) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 Medicine
AU1212501A (en) * 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
DE60318177T2 (en) * 2002-01-23 2008-10-09 Bayer Pharmaceuticals Corp., West Haven RHO-KINASE INHIBITORS
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors

Also Published As

Publication number Publication date
JP4559851B2 (en) 2010-10-13
EP1515965A1 (en) 2005-03-23
WO2003106450A8 (en) 2005-02-03
DE10226943A1 (en) 2004-01-08
WO2003106450A1 (en) 2003-12-24
JP2005538962A (en) 2005-12-22
CA2489452A1 (en) 2003-12-24
CA2489452C (en) 2011-08-23
AU2003232848A1 (en) 2003-12-31
ES2353279T3 (en) 2011-02-28
DE50313157D1 (en) 2010-11-18
EP1515965B1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
HK1087699A1 (en) Gyrase inhibitors and uses thereof
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
EG25482A (en) Inhibitors
PL372814A1 (en) Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
HK1089167A1 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use 2-
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
HK1077762A1 (en) INHIBITORS OF TFGβ
PL374598A1 (en) Caspase inhibitors and uses thereof
IL172257A0 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
AU2003215756A8 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
EP1532133A4 (en) Nf-:b inhibitors
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
PL380189A3 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
EP1583528A4 (en) Nf-kb inhibitors and uses thereof
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
AU2003238948A8 (en) Caspase-1 inhibitors and methods for their use
SI1525200T1 (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0207491D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase